SCHEMBL16184353

SCHEMBL16184353

CNc1nc(-c2cnccn2)nc2c(F)c(-c3ccc(F)c(F)c3)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 5/20 0.40
▸ ALOX5AP P20292 4/20 0.40
▸ GLO1 Q04760 1/20 0.34
▸ LATS1 O95835 1/20 0.34
▸ LATS2 Q9NRM7 1/20 0.34
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ MAT2A P31153 1/20 0.34
▸ PIM1 P11309 1/20 0.33
▸ PIM3 Q86V86 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ WNT3A P56704 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ CHRNA7 P36544 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184363 0.89 SCN9A (0.36) FEN1ALOX5APCYP1A2CYP3A4CYP2D6
SCHEMBL16184340 0.89 NPC1 (0.38) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184351 0.87 NPC1 (0.37) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184343 0.87 WNT1 (0.41) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184348 0.86 NPC1 (0.41) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184357 0.86 CYP1A2 (0.44) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL14474743 0.85 NPC1 (0.42) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184371 0.85 CYP17A1 (0.36) FEN1ALOX5APLATS1LATS2NPC1
SCHEMBL16184347 0.84 SYK (0.41) LATS1LATS2NPC1RAB9ACYP3A4
SCHEMBL16183851 0.84 CYP3A4 (0.50) GLO1LATS1LATS2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB FEN1 3258/4885ALOX5AP 2918/4885GLO1 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback